MetaCap

Apnimed (APMD) vs Kura Oncology (KURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apnimed is the larger company by market cap ($669.8 million vs $634.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APMD-35.64%KURA-23.31%
+56%+4%-48%
Jul 31, 20261 yearNov 20, 2026
APMD-35.64%KURA-23.31%
+51%+4%-44%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APMD versus KURA key metrics
MetricAPMDKURA
Share price$16.09$6.91
Market cap$669.84M$634.88M
1-day change-6.70%-5.99%
YTD return—-33.49%
1-year return—-38.14%
5-year return—-50.66%
P/E ratio (TTM)1.21—
EPS (TTM)$13.34$-3.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$67.48M
Revenue growth (YoY)—+25.24%
Net income (latest FY)—$-278.67M
Operating margin—-449.94%
Net margin—-412.95%
52-week high$35.29$13.90
52-week low$13.88$6.75
Distance from 52-week high-54.41%-50.29%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+210.75%+357.60%
Average volume458.58K2.10M
Shares outstanding41.63M91.88M
Employees112260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Apnimed

APMD stock →

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.

Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees

About Kura Oncology

KURA stock →

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

APMD vs KURA FAQ

Which is bigger, Apnimed or Kura Oncology?

Apnimed (APMD) is larger, with a market capitalization of $669.84M compared with $634.88M for Kura Oncology (KURA).

Are Apnimed and Kura Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons